Key Developments: Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

24.18USD
24 Oct 2014
Price Change (% chg)

$0.08 (+0.33%)
Prev Close
$24.10
Open
$24.14
Day's High
$24.49
Day's Low
$24.07
Volume
26,731
Avg. Vol
68,791
52-wk High
$30.77
52-wk Low
$20.34

Search Stocks

Latest Key Developments (Source: Significant Developments)

Abiomed Inc reiterates FY 2015 revenue guidance
Thursday, 31 Jul 2014 06:59am EDT 

Abiomed Inc:Reiterates its FY 2015 guidance and expects its total revenues to be in the range of $205 million to $212 million.FY 2015 revenue of $209 million - Thomson Reuters I/B/E/S.  Full Article

Abiomed Inc announces acquisition of ECP to broaden and strengthen existing intellectual property and product platform
Tuesday, 1 Jul 2014 04:15pm EDT 

Abiomed Inc:Acquires ECP Entwicklungsgesellschaft mbH (ECP), medical device company based in Berlin, Germany.This acquisition is consistent with Abiomed's strategy to offer percutaneous hemodynamic support for minimally invasive procedures for complex treatment.Additionally, transaction will further strengthen Abiomed's solid position in intellectual property (IP) for axial and expandable pump capabilities.Unique characteristic of the Impella pump is its ability to contain the motor and pump inside the body and be deployed via catheter.In connection with the transaction, Abiomed has acquired all outstanding shares of ECP from Syscore GmbH for about $13 mln in cash, with potential long-term payouts of $7 mln for CE Marking approval and $8 mln for achieving aggregate worldwide revenue of $125 mln for products utilizing ECP patents.In connection with acquisition, Abiomed has also acquired through ECP, AIS GmbH Aachen Innovative Solutions for about $2.75 mln.  Full Article

Abiomed Inc gives FY 2015 revenue outlook below analysts' estimates
Thursday, 1 May 2014 07:03am EDT 

Abiomed Inc:Sees FY 2015 total revenues to be in the range of $205 to $212 million.FY 2015 revenue of $213 mln - Thomson Reuters I/B/E/S.  Full Article

Abiomed Inc acquires license from Opsens Inc
Tuesday, 15 Apr 2014 08:00am EDT 

Abiomed Inc:Announces its acquisition of an exclusive license from collaboration partner Opsens Inc.This licensing agreement, which secures Abiomed's rights to the technology and gives Abiomed the right to manufacture the sensors, is a continuation of an initial collaboration, entered into between Opsens and Abiomed in 2010.  Full Article

Abiomed Inc completes patient enrollment in RECOVER RIGHT Impella Study
Thursday, 20 Mar 2014 08:00am EDT 

Abiomed Inc:Completion of patient enrolled in RECOVER RIGHT, an Investigational Device Exemption (IDE) study of Impella RP (Right Peripheral).The trial was designed to enroll as many as 30 patients, at 15 sites, for up to 14 days of circulatory support.Impella RP is percutaneous heart pump that is implanted through single access site in patient's leg and deployed through the venous system, across the right side of the heart.The device does not require surgical procedure for insertion, and it provides over 4 liters per minute of hemodynamic support.Upon this completion of patient enrollment, Abiomed will be submitting compiled data and seeking approval for Continuous Access Protocol (CAP) to enable the 15 approved Impella RP sites to continue enrolling limited number of patients that meet criteria and protocol.  Full Article

Abiomed Inc maintains FY 2014 revenue outlook
Thursday, 30 Jan 2014 07:03am EST 

Abiomed Inc:Says it is maintaining its FY 2014 guidance.Sees FY 2014 total revenues to be in the range of $180 mln to $185 mln with worldwide Impella revenues increasing about 20 pct.GY 2014 revenue of $183 mln - Thomson Reuters I/B/E/S.  Full Article

Abiomed Inc Maintains FY 2014 Revenue Guidance
Wednesday, 6 Nov 2013 07:00am EST 

Abiomed Inc announced that it is maintaining its fiscal 2014 revenue guidance in the range of $180 million to $185 million, with worldwide Impella revenue forecasted to increase by approximately 20%. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $181 million for fiscal 2014.  Full Article

Abiomed Inc Reaffirms FY 2014 Revenue Guidance
Thursday, 1 Aug 2013 07:02am EDT 

Abiomed Inc maintained its fiscal 2014 revenue guidance in a range of $180 million to $185 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $184 million for fiscal 2014.  Full Article

Abiomed Inc Issues FY 2014 Revenue Guidance In Line With Analysts' Estimates
Thursday, 2 May 2013 07:01am EDT 

Abiomed Inc announced that for fiscal 2014, it expects revenue to be in the range of $180 million to $185 million.According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $181 million for fiscal 2014.  Full Article

Abiomed Inc Reaffirms FY 2013 Revenue Guidance
Wednesday, 6 Feb 2013 07:00am EST 

Abiomed Inc announced that it is maintaining its fiscal 2013 revenue guidance in a range of $155 million to $157 million, representing annual growth of 23% to 24%, with worldwide Impella revenues forecast to grow greater than 30%. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $156 million for fiscal 2013.  Full Article

Search Stocks